New class of monoclonal antibodies against severe influenza: Prophylactic and therapeutic efficacy in ferrets

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Friesen, Robert H E ^a   Koudstaal, Wouter ^a   Koldijk, Martin H ^a   Weverling, Gerrit Jan ^a   Brakenhoff, Just P J ^a   Lenting, Peter J ^a   Stittelaar, Koert J ^b   Osterhaus, Albert D M E ^b,c   Kompier, Ronald ^a   Goudsmit, Jaap ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b ViroClinics BV   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY CR6261; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FERRET; HISTOPATHOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; LUNG; LUNG INJURY; MORTALITY; NONHUMAN; SECRETIONS; SURVIVAL RATE; UPPER RESPIRATORY TRACT; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; WEIGHT REDUCTION; ANIMAL; CELL LINE; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; SWINE; TREATMENT OUTCOME; VIROLOGY;

ANIMALIA; AVES; MUSTELA; ORTHOMYXOVIRIDAE; SUIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; FEMALE; FERRETS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; KAPLAN-MEIERS ESTIMATE; ORTHOMYXOVIRIDAE INFECTIONS; SWINE; TREATMENT OUTCOME;

EID: 77949365750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009106     Document Type: Article

References (34)

1. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3: e3942.
2. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody Recognition of a Highly Conserved Influenza Virus Epitope. Science.
3. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
4. WHO (2009) Fact sheet 211: Influenza. World Health Organization.
5. Hoelscher M, Gangappa S, Zhong W, Jayashankar L, Sambhara S (2008) Vaccines against epidemic and pandemic influenza. Expert Opin Drug Deliv 5: 1139-1157.
6. CDC (2009) Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 58: 400-402.
7. WHO (2009) World now at the start of 2009 influenza pandemic.
8. Salzberg S (2008) The contents of the syringe. Nature 454: 160-161.
9. CDC (2008) Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine-Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 57: 393-398.
10. CDC (2006) Prevention and Control of Influenza; Recommendations of the Advisory Commitee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 55: 1-42.
11. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, et al. (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196: 249-257.
12. He G, Qiao J, Dong C, He C, Zhao L, et al. (2008) Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 77: 72-76.
13. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
14. CDC (2006) High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 55: 44-46.
15. Enserink M (2009) Drug resistance. A 'wimpy' flu strain mysteriously turns scary. Science 323: 1162-1163.
16. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
17. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-1261.
18. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
19. Moscona A (2008) Medical management of influenza infection. Annu Rev Med 59: 397-413.
20. Barnard DL (2009) Animal models for the study of influenza pathogenesis and therapy. Antiviral Res.
21. Hampson AW (2006) Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194: 143-145.
22. van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, et al. (2008) Animal models in influenza vaccine testing. Expert Rev Vaccines 7: 783-793.
23. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, et al. (2008) Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 372: 744-749.
24. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
25. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y (2008) Human infection with highly pathogenic H5N1 influenza virus. Lancet 371: 1464-1475.
26. Thanh TT, van Doorn HR, de Jong MD (2008) Human H5N1 influenza: current insight into pathogenesis. Int J Biochem Cell Biol 40: 2671-2674.
27. Gu J, Xie Z, Gao Z, Liu J, Korteweg C, et al. (2007) H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 370: 1137-1145.
28. Ng WF, To KF, Lam WW, Ng TK, Lee KC (2006) The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1-a review. Hum Pathol 37: 381-390.
29. Uiprasertkul M, Kitphati R, Puthavathana P, Kriwong R, Kongchanagul A, et al. (2007) Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 13: 708-712.
30. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, et al. (2008) Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167: 775-785.
31. Lowen AC, Steel J, Mubareka S, Carnero E, Garcia-Sastre A, et al. (2009) Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol 83: 2803-2818.
32. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, et al. (2004) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363: 2139-2141.
33. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al. (2008) Crossprotection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3: e1401.
34. Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD (1998) Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 74: 57-66.